Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 501,193 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 28,409 · Balance 501,193 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2036-06-15 | Direct | 31,566 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 31,566 · Balance 31,566 F2: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 23:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 31,566 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001493152-26-029416 · ownership.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,566 Underlying: Common stock · 31,566 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 23:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 28,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029416 · ownership.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,193 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 00:35 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 10,000 | $2.98 | $29,801.00 |
DisclosureSEC source: 0001493152-26-026930 · ownership.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 472,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. F2 · price: The weighted average sale price for the transaction reported was $2.9801, and the range of prices were between $2.94 and $3.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:05 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 10,000 | $2.90 | $28,957.00 |
DisclosureSEC source: 0001493152-26-008743 · ownership.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. F2 · price: The weighted average sale price for the transaction reported was $2.8957, and the range of prices were between $2.82 and $3.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 00:00 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 10,000 | $5.00 | $50,008.00 |
DisclosureSEC source: 0001493152-25-025811 · ownership.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. F2 · price: The weighted average sale price for the transaction reported was $5.0008, and the range of prices were between $4.73 and $5.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 28,576 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001641172-25-026003 · ownership.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,576 Underlying: Common stock · 28,576 shares Expires 2035-08-26 F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 22,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-026003 · ownership.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,784 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 06, 2025 Filed Jun 24, 2025 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018048 · form4-06242025_040601.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,501 Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:35 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option Right to Buy) · Derivative | 50,469 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001415889-24-020779 · form4-08052024_100850.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,469 Underlying: Common Stock · 50,469 shares Expires 2034-07-31 F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:35 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 39,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020779 · form4-08052024_100850.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,501 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 01, 2024 Filed Dec 31, 2024 18:20 UTC Amendment | GENELUX Corp GNLX · Entity 1116 | GrantStock Option Right to Buy) · Derivative | 50,469 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-24-030277 · form4a-12312024_011207.xml · derivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,469 Underlying: Common Stock · 50,469 shares Expires 2034-07-31 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:45 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001415889-24-016108 · form4-06072024_090608.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-05-29 F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 13, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs. F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:45 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016108 · form4-06072024_090608.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,960 F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 13, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs. F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:58 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 1,927 | $13.93 | $26,838.68 |
DisclosureSEC source: 0001209191-23-058709 · doc4.xml · nonDerivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463,460 F2 · price: The weighted average sale price for the transaction reported was $13.9277, and the range of prices were between $13.80 and $14.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:58 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 7,073 | $13.23 | $93,548.21 |
DisclosureSEC source: 0001209191-23-058709 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,387 F1 · price: The weighted average sale price for the transaction reported was $13.2261, and the range of prices were between $12.76 and $13.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 22:39 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 881 | $21.30 | $18,768.56 |
DisclosureSEC source: 0001209191-23-052904 · doc4.xml · nonDerivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,460 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $21.3037, and the range of prices were between $21.17 and $21.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 22:39 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 2,452 | $20.50 | $50,269.43 |
DisclosureSEC source: 0001209191-23-052904 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,341 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $20.5014, and the range of prices were between $20.10 and $20.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 00:12 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 3,334 | $24.99 | $83,316.66 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 3 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,793 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:12 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 1,088 | $22.38 | $24,353.57 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,127 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.3838, and the range of prices were between $22.19 and $22.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:12 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 2,245 | $21.67 | $48,642.42 |
DisclosureSEC source: 0001209191-23-049840 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,215 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.667, and the range of prices were between $21.17 and $22.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 00:15 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 4,397 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-23-049365 · doc4.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,397 Underlying: Common Stock · 4,397 shares Expires 2033-09-10 F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 00:15 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 3,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049365 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,460 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 17, 2023 Filed May 2, 2023 20:28 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026507 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,000 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 21:28 UTC | GENELUX Corp GNLX · Entity 1116 | ConversionSeries A Preferred Stock · Derivative | 1,410,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005478 · doc4.xml · derivative · entry 2 Thomas John · CIK 0001939103 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 470,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 21:28 UTC | GENELUX Corp GNLX · Entity 1116 | ConversionCommon Stock | 470,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005478 · doc4.xml · nonDerivative · entry 1 Thomas John · CIK 0001939103 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.